To include your compound in the COVID-19 Resource Center, submit it here.

Gilead's simtuzumab misses in pancreatic cancer

Gilead Sciences Inc. (NASDAQ:GILD) said simtuzumab ( GS-6624) missed the primary endpoint of progression-free survival (PFS) in a Phase

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE